GlassScriptPhysician profile
John C Wohar
NPI 1578794244
$1,131.19
in general payments reported to CMS, 2019-2025
15 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $48.16 · 2021: $18.08 · 2022: $145 · 2023: $231 · 2024: $219 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571 · Education: $84.99 · Debt Forgiveness: $60.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $571.18 |
| Education | $84.99 |
| Debt Forgiveness | $60.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $279.95 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $162.26 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $157.75 | 2022-2024 | Arexvy, Shingrix |
| Novo Nordisk INC | $125.43 | 2020-2025 | Ozempic, Rybelsus |
| Amgen INC. | $90.31 | 2019-2024 | Repatha, Otezla |
| Lilly USA, LLC | $81.03 | 2020-2025 | Mounjaro |
| Baxter Healthcare | $60.77 | 2025 | |
| Janssen Pharmaceuticals, INC | $35.28 | 2019-2022 | |
| Abbott Laboratories | $35.01 | 2022-2023 | Freestyle Libre 3 |
| Heartflow, INC. | $23.90 | 2023 | Ffrct |
| United Therapeutics Corporation | $18.08 | 2021 | |
| Merck Sharp & Dohme LLC | $17.15 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.00 | 2022 | |
| Pfizer INC. | $15.74 | 2025 | |
| Circassia INC. | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wohar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.